Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1600RXA

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	DEC 01	ChemPort single article sales feature unavailable
NEWS	3	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS	4	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS	5	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS	6	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS	7	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS	8	FEB 10	COMPENDEX reloaded and enhanced
NEWS	9	FEB 11	WTEXTILES reloaded and enhanced
NEWS	10	FEB 19	New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art
NEWS	11	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS	12	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS	13	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS	14	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS	15	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS	16	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS	17	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS	18	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS	19	MAR 11	ESBIOBASE reloaded and enhanced
NEWS	20	MAR 20	CAS databases on STN enhanced with new super role for nanomaterial substances
NEWS	21	MAR 23	CA/CAplus enhanced with more than 250,000 patent equivalents from China
NEWS	22	MAR 30	IMSPATENTS reloaded and enhanced
NEWS	23	APR 03	CAS coverage of exemplified prophetic substances enhanced
NEWS	24	APR 07	STN is raising the limits on saved answers

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 08:09:35 ON 17 APR 2009

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 08:10:02 ON 17 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 APR 2009 HIGHEST RN 1135193-69-9
DICTIONARY FILE UPDATES: 15 APR 2009 HIGHEST RN 1135193-69-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\QUERIES\10511065.str



chain nodes :
1 2 3 4 5 6 13 14 15
ring nodes :
7 8 9 10 11 12
chain bonds :
1-14 2-13 2-3 2-14 3-4 4-5 4-7 5-6 5-15
ring bonds :
7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
1-14 2-13 2-3 2-14 3-4 4-5 4-7 5-6 5-15 7-8 7-12 8-9 9-10 10-11 11-12

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS

L1   STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1   STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 08:10:47 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      220 TO ITERATE

100.0% PROCESSED      220 ITERATIONS                                1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         3511 TO     5289
PROJECTED ANSWERS:               1 TO       80

L2             1 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 08:10:50 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     4430 TO ITERATE

100.0% PROCESSED     4430 ITERATIONS                              34 ANSWERS
SEARCH TIME: 00.00.01

L3            34 SEA SSS FUL L1

=> s l3 and caplus/lc
      65189794 CAPLUS/LC
L4           32 L3 AND CAPLUS/LC

=> s l3 not l4
L5            2 L3 NOT L4
```

```
=> d l5 1-2
```

L5 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2009 ACS on STN
RN 1027089-49-1 REGISTRY
ED Entered STN: 10 Jun 2008
CN 2-Piperidinecarboxylic acid, 1-[(2S,3S)-2-(4-chlorophenyl)-3-[(hydroxyamino)carbonyl]-1-oxopentyl]-, (2S)- (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H23 Cl N2 O5
SR Other Sources
Database: ChemSpider (ChemZoo, Inc.)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2009 ACS on STN
RN 612840-63-8 REGISTRY
ED Entered STN: 05 Nov 2003
CN 1-Piperazinebutanamide, β-(4-chlorophenyl)-α-ethyl-N-hydroxy-2-[[(2-methylpropyl)amino]carbonyl]-γ-oxo-, (αS,βS,2S)- (CA INDEX NAME)
FS STEREOSEARCH
MF C21 H31 Cl N4 O4
CI COM
SR CA

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

```
=> fil caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   197.25     197.47

FILE 'CAPLUS' ENTERED AT 08:13:09 ON 17 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 17 Apr 2009  VOL 150 ISS 17
FILE LAST UPDATED: 16 Apr 2009  (20090416/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d his

     (FILE 'HOME' ENTERED AT 08:09:35 ON 17 APR 2009)

     FILE 'REGISTRY' ENTERED AT 08:10:02 ON 17 APR 2009
L1              STRUCTURE UPLOADED
L2            1 S L1
L3           34 S L1 FULL
L4           32 S L3 AND CAPLUS/LC
L5            2 S L3 NOT L4

     FILE 'CAPLUS' ENTERED AT 08:13:09 ON 17 APR 2009

=> s l4
L6            7 L4

=> d ibib abs hitstr 1-7
```

L6 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:761946 CAPLUS
DOCUMENT NUMBER: 145:356718
TITLE: Rapid Assembly of Matrix Metalloprotease Inhibitors Using Click Chemistry
AUTHOR(S): Wang, Jun; Uttamchandani, Mahesh; Li, Junqi; Hu, Mingyu; Yao, Shao Q.
CORPORATE SOURCE: Departments of Chemistry and Biological Sciences, Medicinal Chemistry Program of the Office of Life Sciences, National University of Singapore, Singapore, 117543, Singapore
SOURCE: Organic Letters (2006), 8(17), 3821-3824
CODEN: ORLEF7; ISSN: 1523-7060
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 145:356718
AB A panel of 96 metalloprotease inhibitors was assembled using click chemical by reacting eight zinc-binding hydroxamate warheads with 12 azide building blocks. Screens of the bidentate compds. against representative metalloproteases provided discerning inhibition fingerprints, revealing compds. with low micromolar potency against MMP-7. The relative ease and convenience of the strategy in constructing focused chemical libraries for rapid in situ screening of MMPs is thereby demonstrated.
IT 910581-27-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(rapid assembly of triazolealkanamide derivs. as matrix metalloprotease inhibitors using click chemical)
RN 910581-27-0 CAPLUS
CN 3-Oxazolidinebutanamide, β-cyclohexyl-γ,2-dioxo-N-(triphenylmethoxy)- (CA INDEX NAME)



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:315131 CAPLUS
DOCUMENT NUMBER: 145:20401
TITLE: A cassette-dosing approach for improvement of oral bioavailability of dual TACE/MMP inhibitors
AUTHOR(S): Janser, Philipp; Neumann, Ulf; Miltz, Wolfgang; Feifel, Roland; Buhl, Thomas
CORPORATE SOURCE: Novartis Institutes for BioMedical Research, Basel, CH-4002, Switz.
SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(10), 2632-2636
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 145:20401
GI



AB The structural features contributing to the different pharmacokinetic properties of the TACE/MMP inhibitors TNF484 and Trocade were analyzed using an in vivo cassette-dosing approach in rats. This enabled us to identify a new lead compound (I) with excellent pharmacokinetic properties, but weaker activity on the biol. targets. Directed structural modifications maintained oral bioavailability and restored biol. activity, leading to a novel compound (II) almost equipotent to TNF484 in vivo, but with a more than tenfold higher oral bioavailability.
IT 612840-61-6P 612840-66-1P 612840-67-2P
888490-49-1P 888490-50-4P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(cassette-dosing approach for improvement of oral bioavailability of dual TACE/MMP inhibitors)
RN 612840-61-6 CAPLUS
CN 1-Piperidinebutanamide, N-hydroxy-α-(hydroxymethyl)-β-(4-methoxyphenyl)-γ-oxo-, (αR,βS)- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 612840-66-1 CAPLUS
CN 1-Piperidinebutanamide, N-hydroxy-α-(hydroxymethyl)-β-(4-methoxyphenyl)-2-[(methylamino)carbonyl]-γ-oxo-, (αR,βS,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 612840-67-2 CAPLUS
CN 1-Piperidinebutanamide, α-ethyl-N-hydroxy-β-(4-methoxyphenyl)-2-[(methylamino)carbonyl]-γ-oxo-, (αS,βS,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 888490-49-1 CAPLUS
CN 1-Piperidinebutanamide, N-hydroxy-β-(4-methoxyphenyl)-γ-oxo-α-[(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)methyl]-, (αR,βS)- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 888490-50-4 CAPLUS
CN 1-Piperidinebutanamide, β-(4-chlorophenyl)-α-ethyl-N-hydroxy-2-[(methylamino)carbonyl]-γ-oxo-, (αS,βS,2S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:818409 CAPLUS
DOCUMENT NUMBER: 139:323538
TITLE: Preparation of hydroxamic acid derivatives for use as pharmaceuticals
INVENTOR(S): Janser, Philipp; Miltz, Wolfgang; Neumann, Ulf
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003084941	A2	20031016	WO 2003-EP3644	20030408
WO 2003084941	A3	20040325		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
CA 2481879	A1	20031016	CA 2003-2481879	20030408
AU 2003236834	A1	20031020	AU 2003-236834	20030408
EP 1497273	A2	20050119	EP 2003-735343	20030408
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003009135	A	20050201	BR 2003-9135	20030408
CN 1649857	A	20050803	CN 2003-809483	20030408
CN 100345834	C	20071031		
JP 2005528381	T	20050922	JP 2003-582138	20030408
US 20060063778	A1	20060323	US 2005-511065	20051003

PRIORITY APPLN. INFO.: GB 2002-8176 A 20020409
WO 2003-EP3644 W 20030408

OTHER SOURCE(S): MARPAT 139:323538
GI



I

AB Novel hydroxamic acid derivs., e.g., I [X = null or CH2; Z = CH2, O, S, NH

L6 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

or derivs.; R1 = (un)substituted alkyl, cycloalkyl, heterocycloalkyl or aryl; R2 = H, CR6R7-Q-R8, CO-Q-R8, CS-Q-R8, where R6, R7 = groups given for R1 and R8 = (un)substituted alkyl, cycloalkyl, aryl, or arylalkyl; R3, R4 = H or alkyl; R5 = halo, cyano, alkyl, haloalkyl, aryl, OH, etc.], were prepd. for use as pharmaceuticals, e.g., for the suppression of TNF release and the treatment of autoimmune and inflammatory diseases, e.g., multiple sclerosis and rheumatoid arthritis. Thus, 3(S)-(4-chlorophenyl)-2(S)-ethyl-N-hydroxy-4-morpholino-4-oxobutyramide was prepd. by amidation of 2(S)-(4-chlorophenyl)-3(R)-ethyl-4-pentenoic acid (prepn. given) with morpholine, followed by oxidn. of the double bond and hydroxyamidation. Compds. of the invention suppress TNF release with an IC50 of .apprx. 50 nM to .apprx. 5 pM and inhibit collagenase at concns. < 10 nM.

IT 612840-60-5P 612840-62-7P 612840-65-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of hydroxamic acid derivs. for use as pharmaceuticals)

RN 612840-60-5 CAPLUS
CN 1-Piperidinebutanamide, N-hydroxy-β-(4-methoxyphenyl)-γ-oxo-α-[(phenylmethoxy)methyl]-, (αR,βS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 612840-62-7 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[(2S,3S)-2-(4-chlorophenyl)-3-[(hydroxyamino)carbonyl]-1-oxopentyl]-3-[[(2-methylpropyl)amino]carbonyl]-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 612840-65-0 CAPLUS
CN 1-Piperidinebutanamide, N-hydroxy-β-(4-methoxyphenyl)-2-[(methylamino)carbonyl]-γ-oxo-α-[(phenylmethoxy)methyl]-, (αR,βS,2S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 612036-83-6P 612840-58-1P 612840-59-2P
612840-61-6P 612840-64-9P 612840-66-1P
612840-67-2P 612840-68-3P 612840-69-4P
612840-70-7P 612840-71-8P 612840-72-9P
612840-73-0P 612840-74-1P 612840-75-2P
612840-76-3P 612840-77-4P 612840-78-5P
612840-79-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydroxamic acid derivs. for use as pharmaceuticals)

RN 612036-83-6 CAPLUS
CN 1-Piperidinebutanamide, β-(4-chlorophenyl)-α-ethyl-N-hydroxy-2-[[(1-methylethyl)amino]carbonyl]-γ-oxo-, (αS,βS,2S)- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 612840-58-1 CAPLUS
CN 4-Morpholinebutanamide, β-(4-chlorophenyl)-α-ethyl-N-hydroxy-γ-oxo-, (αS,βS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 612840-59-2 CAPLUS
CN 1-Piperazinebutanamide, 4-(4-chlorophenyl)-N-hydroxy-β-(4-methoxyphenyl)-γ-oxo-α-[(phenylmethoxy)methyl]-, (αR,βS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 612840-61-6 CAPLUS
CN 1-Piperidinebutanamide, N-hydroxy-α-(hydroxymethyl)-β-(4-methoxyphenyl)-γ-oxo-, (αR,βS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 612840-64-9 CAPLUS
CN 1-Piperazinebutanamide, β-(4-chlorophenyl)-α-ethyl-N-hydroxy-2-[[(2-methylpropyl)amino]carbonyl]-γ-oxo-, (αS,βS,2S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 612840-63-8
CMF C21 H31 Cl N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 612840-66-1 CAPLUS
CN 1-Piperidinebutanamide, N-hydroxy-α-(hydroxymethyl)-β-(4-methoxyphenyl)-2-[(methylamino)carbonyl]-γ-oxo-, (αR,βS,2S)- (CA INDEX NAME)

Absolute stereochemistry.

Absolute stereochemistry.



RN 612840-70-7 CAPLUS
CN 1-Piperidinebutanamide, α-ethyl-N-hydroxy-2-[[(trans-4-hydroxycyclohexyl)amino]carbonyl]-β-(4-methoxyphenyl)-γ-oxo-, (αS,βS,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 612840-71-8 CAPLUS
CN 1-Piperidinebutanamide, α-ethyl-N-hydroxy-β-(4-methoxyphenyl)-γ-oxo-2-[[(phenylmethyl)amino]carbonyl]-, (αS,βS,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 612840-72-9 CAPLUS
CN 1-Piperidinebutanamide, α-ethyl-2-[[(4-fluorophenyl)amino]carbonyl]-N-hydroxy-β-(4-methoxyphenyl)-γ-oxo-, (αS,βS,2S)- (CA INDEX NAME)



RN 612840-67-2 CAPLUS
CN 1-Piperidinebutanamide, α-ethyl-N-hydroxy-β-(4-methoxyphenyl)-2-[(methylamino)carbonyl]-γ-oxo-, (αS,βS,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 612840-68-3 CAPLUS
CN 1-Piperidinebutanamide, 2-[(cyclopropylamino)carbonyl]-α-ethyl-N-hydroxy-β-(4-methoxyphenyl)-γ-oxo-, (αS,βS,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 612840-69-4 CAPLUS
CN 1-Piperidinebutanamide, α-ethyl-N-hydroxy-2-[[(2-methoxyethyl)amino]carbonyl]-β-(4-methoxyphenyl)-γ-oxo-, (αS,βS,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 612840-73-0 CAPLUS
CN 1-Piperidinebutanamide, β-(4-chlorophenyl)-2-[(cyclopropylamino)carbonyl]-α-ethyl-N-hydroxy-γ-oxo-, (αS,βS,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 612840-74-1 CAPLUS
CN 1-Piperidinebutanamide, β-(4-chlorophenyl)-α-ethyl-N-hydroxy-2-[[[3-(1-methylethoxy)propyl]amino]carbonyl]-γ-oxo-, (αS,βS,2S)- (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 612840-75-2 CAPLUS
CN 1-Piperidinebutanamide, β-(4-chlorophenyl)-α-ethyl-N-hydroxy-2-[[(trans-4-hydroxycyclohexyl)amino]carbonyl]-γ-oxo-, (αS,βS,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 612840-76-3 CAPLUS
CN 1-Piperidinebutanamide, β-(4-chlorophenyl)-α-ethyl-N-hydroxy-γ-oxo-2-[[(phenylmethyl)amino]carbonyl]-, (αS,βS,2S)-(CA INDEX NAME)

Absolute stereochemistry.



RN 612840-77-4 CAPLUS
CN 1-Piperidinebutanamide, β-(4-chlorophenyl)-α-ethyl-N-hydroxy-γ-oxo-2-[(phenylamino)carbonyl]-, (αS,βS,2S)- (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 612840-78-5 CAPLUS
CN 1-Pyrrolidinebutanamide, α-ethyl-N-hydroxy-β-(4-methoxyphenyl)-γ-oxo-2-[(phenylamino)carbonyl]-, (αS,βS,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 612840-79-6 CAPLUS
CN 1-Pyrrolidinebutanamide, β-(4-chlorophenyl)-α-ethyl-N-hydroxy-2-[[[(2S)-2-hydroxypropyl]amino]carbonyl]-γ-oxo-, (αS,βS,2S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L6 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:818289 CAPLUS
DOCUMENT NUMBER: 139:302067
TITLE: Methods for the treatment of chronic pain with MMP7 inhibitors and compositions therefor
INVENTOR(S): Buxton, Francis Paul; Fox, Alyson; Ganju, Pamposh; Gray, Andrew J.; Song, Chuanzheng; Urban, Laszlo
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003084540	A2	20031016	WO 2003-EP3643	20030408
WO 2003084540	A3	20040401		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
AU 2003224052	A1	20031020	AU 2003-224052	20030408
EP 1496901	A2	20050119	EP 2003-720437	20030408
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005526820	T	20050908	JP 2003-581780	20030408
US 20060178323	A1	20060810	US 2005-510530	20050413
PRIORITY APPLN. INFO.:			US 2002-371042P P	20020409
			WO 2003-EP3643 W	20030408

AB The invention discloses MMP7 as a suitable target for the development of new therapeutics to treat or ameliorate chronic pain. The invention relates to methods to treat and/or ameliorate chronic pain and pharmaceutical compns. therefor comprising modulators with inhibitory effect on MMP7 enzyme activity and/or MMP7 gene expression. The invention also relates to a method to identify compds. with therapeutic usefulness to treat chronic pain, comprising identifying compds. that can inhibit MMP7 activity and/or gene expression which can also reverse the pathol. effects of chronic pain in vivo.

IT 612036-83-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods for treatment of chronic pain with MMP7 inhibitors)

RN 612036-83-6 CAPLUS
CN 1-Piperidinebutanamide, β-(4-chlorophenyl)-α-ethyl-N-hydroxy-2-[[(1-methylethyl)amino]carbonyl]-γ-oxo-, (αS,βS,2S)- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L6 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1993:124430 CAPLUS
DOCUMENT NUMBER: 118:124430
ORIGINAL REFERENCE NO.: 118:21569a,21572a
TITLE: Reaction of carboxylic esters and carbonyl derivatives
with dilithiated benzyl hydroximate: a novel route for synthesis of 1,2-oxazoles and 4,5-dihydro-1,2-oxazoles
AUTHOR(S): M'rabet, H.; Amor, A. Bel Hadj; Baccar, B.
CORPORATE SOURCE: Lab. Synth. Org., Fac. Sci. Tunis, Tunis, 1060, Tunisia
SOURCE: Journal de la Societe Chimique de Tunisie (1991), 3(2), 89-96
CODEN: JSCTDP; ISSN: 0253-1208
DOCUMENT TYPE: Journal
LANGUAGE: French
GI



AB Lithiation of PhCH2C(OEt):NOH and reaction with RCO2Et (R = H, Me, Et, Ph)
gave HOCR:CPhC(OEt):NOH which were cyclized to isoxazoles I. Isoxazoles II (R1 = H, Me, Et; R2 = Ph, 4-ClC6H4, Me, Et) were similarly obtained from R1R2CO and PhCH2C(OEt):NOH.
IT 146197-24-2P 146197-29-7P 146197-30-0P
146197-31-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclization of)
RN 146197-24-2 CAPLUS
CN Benzeneethanimidic acid, N-hydroxy-α-(hydroxyphenylmethylene)-, ethyl ester (CA INDEX NAME)



RN 146197-29-7 CAPLUS
CN Benzenepropanimidic acid, N,β-dihydroxy-α-phenyl-, ethyl ester (CA INDEX NAME)



RN 146197-30-0 CAPLUS
CN Benzenepropanimidic acid, 4-chloro-N,β-dihydroxy-α-phenyl-,

L6 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
ethyl ester (CA INDEX NAME)



RN 146197-31-1 CAPLUS
CN Benzenepropanimidic acid, N,β-dihydroxy-β-methyl-α-phenyl-, ethyl ester (CA INDEX NAME)



L6 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1983:405478 CAPLUS
DOCUMENT NUMBER: 99:5478
ORIGINAL REFERENCE NO.: 99:997a,1000a
TITLE: Preparation and reactions of 3,4-dihydro-2H-pyran-2-ones
AUTHOR(S): El-Kholy, Ibrahim El-Sayed; Mishrikey, Morcos Michael;
Abdoul-Ela, Salah Loutfi
CORPORATE SOURCE: Fac. Sci., Alexandria Univ., Alexandria, Egypt
SOURCE: Journal of Heterocyclic Chemistry (1982), 19(6), 1329-34
CODEN: JHTCAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 99:5478
GI



AB Michael reaction of 4-RC6H4CH:CHCO2Et (R = H, MeO) with deoxybenzoin gave 4-RC6H4CH(CH2CO2Et)CHPhCOPh which were hydrolyzed to the corresponding acids. The latter could be cyclized to the dihydropyranones I (X = O) which underwent ring opening with nucleophiles to give 4-RC6H4CH(CH2COR1)CHPhCOPh (R1 = NH2, PhNH, Me2N, H2NNH, HONH, piperidino). However, their reaction with NH4OAc gave I (X = NH). I (X = O, NH) were dehydrogenated to 2-pyrones and 2-pyridones by fusion with sulfur.
IT 85503-41-9P 85503-42-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 85503-41-9 CAPLUS
CN Benzenepentanamide, N-hydroxy-δ-oxo-β,γ-diphenyl- (CA INDEX NAME)



RN 85503-42-0 CAPLUS
CN Benzenepentanamide, N-hydroxy-β-(4-methoxyphenyl)-δ-oxo-γ-phenyl- (CA INDEX NAME)

L6 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L6 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1968:86992 CAPLUS
DOCUMENT NUMBER: 68:86992
ORIGINAL REFERENCE NO.: 68:16751a,16754a
TITLE: Electrochemical reduction of phenylglyoxylamide and phenylglyoxylhydroxamic acid
AUTHOR(S): Armand, Joseph; Souchay, Pierre; Valentini, Francoise
CORPORATE SOURCE: Fac. Sci., Paris, Fr.
SOURCE: Comptes Rendus des Seances de l'Academie des Sciences,
Serie C: Sciences Chimiques (1967), 265(22), 1267-70
CODEN: CHDCAQ; ISSN: 0567-6541
DOCUMENT TYPE: Journal
LANGUAGE: French
AB The electrochem. reduction of PhCOCONH2 at a Hg cathode gave 70% PhCH(OH)CONH2 (I) and 20% pure diastereoisomeric diphenyltartramide (II), m. 227°. Chemical reduction of the starting compound gave only 70% I. Treatment of II with HCN followed by hydration gave [PhC(OH)CONH2]2. Electrochem. reduction of PhCOCONHOH gave I and HONHCO[CPh(OH)]2CONH2, m. 210°. Chemical reduction of the hydroxamic acid with Zn and H2SO4 gave 70% I. The reaction mechanisms were discussed.
IT 1081527-64-1P
RL: SPN (Synthetic preparation); PRP (Properties); PREP (Preparation)
(Electrochemical reduction of phenylglyoxylamide and phenylglyoxylhydroxamic acid)
RN 1081527-64-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



```
=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    44.48     241.95

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -5.74      -5.74

STN INTERNATIONAL LOGOFF AT 08:19:24 ON 17 APR 2009
```